GI-RADS联合血清肿瘤标志物鉴别卵巢肿块良恶性的价值

Clinical Application Value of GI-RADS Reporting System Combinedwith Serum Tumor Markers in Differentiating Benign andMalignant Ovarian Masses

本研究探讨妇科影像报告与数据系统(GI-RADS)联合血清肿瘤标志物在卵巢肿块良恶性鉴别诊断中的应用价值。回顾分析卵巢肿块患者132例的超声影像资料。良性肿块患者90例,恶性肿块患者42例;GI-RADS联合血清肿瘤标志物以并联方式诊断恶性的灵敏性、特异性、准确性、阳性预测值和阴性预测值分别为83.33%、74.44%、77.27%、60.34%和90.54%;以串联方式诊断恶性的灵敏性、特异性、准确性、阳性预测值和阴性预测值分别为64.29%、90.00%、81.82%、75.00%和84.38%。GI-RADS联合血清肿瘤标志物鉴别诊断卵巢肿块良恶性具有较好的临床应用价值。

This study was to investigate the value of gynecological imaging reporting and data system(GI-RADS)combined with serum tumor markers in the differential diagnosis of benign and malignant ovarian masses.The ultrasonic imaging data of 132 patients with ovarian masses were reviewed.There were 90 patients with benign masses and 42 patients with malignant masses.the sensitivity,specificity,accuracy,positive predictive value and negative predictive value of parallel diagnosis of GI-RADS combined with serum tumor markers were 83.33%,74.44%,77.27%,60.34%and 90.54%,respectively.The sensitivity,specificity,accuracy,positive predictive value and negative predictive value of tandem method were 64.29%,90.00%,81.82%,75.00%and 84.38%,respectively.GI-RADS combined with serum tumor markers has good clinical application value in the differential diagnosis of benign and malignant ovarian masses.